Literature DB >> 10360319

Leukocidal toxins of staphylococci.

S Szmigielski1, G Prévost, H Monteil, D A Colin, J Jeljaszewicz.   

Abstract

Leukocidal toxins (synergohymenotropic toxin) are cytotoxins produced by staphylococci (S. aureus and S. intermedius) and consist of two separate components. The toxic effect depends on the synergistic action of two proteins. One of them belongs to class F (e.g. LukF-PV, LukF-R, LukF-I, LukM, HlgB) and the other, to class S (e.g. LukS-PV, LukS-R, LukS-I, HlgA, HlgC). Best known are the toxins produced by S. aureus: gamma-haemolysins, HlgA/HlgB and HlgC/HlgB and leukocidin Panton-Valentine, LukS-PV/LukF-PV (Luk-PV, PVL). Very few data are available concerning the relationship between the production of these toxins and the pathology of staphylococcal infections, because little is known about local and general effects of these leukocidal products in vivo. Frequent isolations of staphylococcal strains producing leukocidal toxins from necrotic skin lesions and furuncles suggest a role of these toxins in the virulence of staphylococci, at least in cutaneous infections. Recent data on mechanisms of cytotoxic effects of staphylococcal leukocidal toxins in vitro as well as effects of leukocidal toxins in vitro are discussed. Cell membranes appear to be a primary target for triggering the lysis of phagocytic cells caused by staphylococcal leukocidal toxins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360319     DOI: 10.1016/s0934-8840(99)80105-4

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  39 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

Review 2.  Novel targeted immunotherapy approaches for staphylococcal infection.

Authors:  Michael Otto
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

3.  Relative contribution of Panton-Valentine leukocidin to PMN plasma membrane permeability and lysis caused by USA300 and USA400 culture supernatants.

Authors:  Shawna F Graves; Scott D Kobayashi; Kevin R Braughton; Binh An Diep; Henry F Chambers; Michael Otto; Frank R Deleo
Journal:  Microbes Infect       Date:  2010-02-19       Impact factor: 2.700

4.  Painful nodule with induration and spreading erythema.

Authors:  Elizabeth Race; Cindy Berthelot; Jennifer Clay Cather
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

Review 5.  The bicomponent pore-forming leucocidins of Staphylococcus aureus.

Authors:  Francis Alonzo; Victor J Torres
Journal:  Microbiol Mol Biol Rev       Date:  2014-06       Impact factor: 11.056

Review 6.  Mechanisms of bacterial virulence in pulmonary infections.

Authors:  Samuel M Moskowitz; Jeanine P Wiener-Kronish
Journal:  Curr Opin Crit Care       Date:  2010-02       Impact factor: 3.687

7.  Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia.

Authors:  Binh An Diep; Anna Afasizheva; Hoan N Le; Osamu Kajikawa; Gustavo Matute-Bello; Christine Tkaczyk; Bret Sellman; Cedric Badiou; Gerard Lina; Henry F Chambers
Journal:  J Infect Dis       Date:  2013-03-26       Impact factor: 5.226

Review 8.  Mobile genetic elements of Staphylococcus aureus.

Authors:  Natalia Malachowa; Frank R DeLeo
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

Review 9.  The role of virulence determinants in community-associated MRSA pathogenesis.

Authors:  Binh An Diep; Michael Otto
Journal:  Trends Microbiol       Date:  2008-06-26       Impact factor: 17.079

10.  Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury.

Authors:  Ching Wen Tseng; Pierre Kyme; Jennifer Low; Miguel A Rocha; Randa Alsabeh; Loren G Miller; Michael Otto; Moshe Arditi; Binh An Diep; Victor Nizet; Terence M Doherty; David O Beenhouwer; George Y Liu
Journal:  PLoS One       Date:  2009-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.